Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Curis (NASDAQ:CRIS) in a research note released on Friday, Benzinga reports. HC Wainwright currently has a $26.00 target price on the biotechnology company’s stock.

Curis Trading Up 0.2 %

NASDAQ:CRIS opened at $5.39 on Friday. The stock has a market capitalization of $31.77 million, a P/E ratio of -0.64 and a beta of 3.33. Curis has a 1 year low of $3.80 and a 1 year high of $17.49. The firm has a 50 day moving average of $5.34 and a 200-day moving average of $9.12.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.36). Curis had a negative return on equity of 327.92% and a negative net margin of 468.18%. The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $2.20 million. During the same period in the prior year, the firm posted ($2.40) EPS. As a group, analysts forecast that Curis will post -6.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Curis

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in shares of Curis in the 1st quarter valued at $219,000. Point72 Asset Management L.P. raised its position in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after acquiring an additional 96,256 shares during the last quarter. CM Management LLC lifted its stake in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares during the period. Finally, Focused Wealth Management Inc boosted its holdings in Curis by 79.2% in the first quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 14,656 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.